Scarica l'app Stockscreener
2.79
1.06%
-0.03
Dopo l'orario di chiusura:
2.84
0.05
+1.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.82
Aprire:
$2.87
Volume 24 ore:
69,665
Relative Volume:
1.24
Capitalizzazione di mercato:
$89.87M
Reddito:
-
Utile/perdita netta:
$-12.48M
Rapporto P/E:
-7.1538
EPS:
-0.39
Flusso di cassa netto:
$-7.93M
1 W Prestazione:
+9.84%
1M Prestazione:
+0.36%
6M Prestazione:
-13.89%
1 anno Prestazione:
+9.41%
Intervallo 1D:
$2.71
$2.87
Intervallo di 1 settimana:
$2.5003
$3.05
Portata 52W:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Nome
Anixa Biosciences Inc
Settore
Industria
Telefono
408-708-9808
Indirizzo
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Confronta ANIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.79 | 81.82M | 0 | -12.48M | -7.93M | -0.39 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-21 | Iniziato | Maxim Group | Buy |
| 2022-12-23 | Iniziato | Chardan Capital Markets | Buy |
| 2021-04-12 | Iniziato | H.C. Wainwright | Buy |
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
Northern Trust Corp Trims Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Hits Major Milestone: Phase 1 Trial Fully Enrolled - Stock Titan
Anixa Biosciences Announces Completion Of Enrollment In Phase 1 Trial Of Breast Cancer Vaccine - marketscreener.com
Anixa Biosciences (ANIX) Concludes Enrollment for Breast Cancer Vaccine Trial | ANIX Stock News - GuruFocus
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Vaccine Achieves Major Milestone: 70% of Patients Show Promising Immune Response - Stock Titan
ANIXA BIOSCIENCES Earnings Preview: Recent $ANIX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - marketscreener.com
Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Tar - GuruFocus
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Anixa Biosciences Inc SEC 10-Q Report - TradingView
Anixa Biosciences (ANIX) Expected to Announce Earnings on Tuesday - Defense World
Anixa Biosciences CEO Provides Letter to Shareholders Outlining - GuruFocus
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones - Nasdaq
Anixa Biosciences Announces Poster Presentation on Ovarian Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting - Stock Titan
Renaissance Technologies LLC Has $34,000 Stock Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Acquired by LPL Financial LLC - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual B - GuruFocus
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th - Nasdaq
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up - MSN
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium - Seeking Alpha
Anixa Biosciences (ANIX) Secures Patent to Advance CAR-T Cancer Therapy | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent - GuruFocus
Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent - marketscreener.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio - Finansavisen
Major Patent Win: Anixa's Revolutionary CAR-T Cancer Treatment Gains Key Protection - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting - marketscreener.com
Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from D. Boral Capital - Defense World
Anixa Biosciences Stock Price, Quotes and Forecasts - Benzinga
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Anixa gains US patent for breast cancer vaccine technology - Investing.com Australia
Anixa gains US patent for breast cancer vaccine technology By Investing.com - Investing.com Canada
Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine - marketscreener.com
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent - AOL.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology - BioSpace
Anixa Biosciences stock rises on patent win (ANIX:NASDAQ) - Seeking Alpha
Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office - MarketScreener
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital - Defense World
What is HC Wainwright’s Forecast for ANIX Q1 Earnings? - Defense World
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Anixa Biosciences Inc Azioni (ANIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):